HEE SO: Open Payments
NPI 1215080270 · JERSEY CITY, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$397 in 23 payments from 11 companies in 2025. Trend: 2023 $193 · 2024 $479 · 2025 $397
Food & beverage: $397
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $96 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| Neurocrine BioSciences, Inc. | 2 | $37 |
| Axsome Therapeutics, Inc. | 2 | $36 |
| Supernus Pharmaceuticals, Inc. | 2 | $36 |
| ABBVIE INC. | 2 | $32 |
| Tris Pharma Inc | 2 | $32 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $19 |
| Bausch Health US, LLC | 1 | $19 |
| Lundbeck LLC | 1 | $17 |
Products named: TRINTELLIX, REXULTI, INGREZZA, Auvelity, Qelbree, VRAYLAR, Dyanavel XR, CAPLYTA.
Industry payments across NJ — which companies pay providers there.
